Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

(+)alpha-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo

Full text
Author(s):
Show less -
dos Santos, G. A. S. [1, 2] ; Abreu e Lima, R. S. [1] ; Pestana, C. R. [2] ; Lima, A. S. G. [1] ; Scheucher, P. S. [1] ; Thome, C. H. [1] ; Gimenes-Teixeira, H. L. [1] ; Santana-Lemos, B. A. A. [1] ; Lucena-Araujo, A. R. [1] ; Rodrigues, F. P. [2] ; Nasr, R. [3, 4] ; Uyemura, S. A. [5] ; Falcao, R. P. [1] ; de The, H. [4] ; Pandolfi, P. P. [6] ; Curti, C. [2] ; Rego, E. M. [1]
Total Authors: 17
Affiliation:
[1] Univ Sao Paulo, Div Hematol, Natl Inst Sci & Technol Cell Based Therapy, Dept Internal Med, Med Sch Ribeirao Preto, BR-14049 Ribeirao Preto - Brazil
[2] Univ Sao Paulo, Dept Phys & Chem, Pharmaceut Sci Fac Ribeirao Preto, BR-14049 Ribeirao Preto - Brazil
[3] Amer Univ Beirut, Dept Internal Med, Beirut - Lebanon
[4] Lab Associe Com Paris Ligue Canc, CNRS, UMR 7151, Paris - France
[5] Univ Sao Paulo, Dept Clin Toxicol & Bromatol Anal, Pharmaceut Sci Fac Ribeirao Preto, BR-14049 Ribeirao Preto - Brazil
[6] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 - USA
Total Affiliations: 6
Document type: Journal article
Source: LEUKEMIA; v. 26, n. 3, p. 451-460, MAR 2012.
Web of Science Citations: 36
Abstract

The vitamin E derivative (+)alpha-tocopheryl succinate (alpha-TOS) exerts pro-apoptotic effects in a wide range of tumors and is well tolerated by normal tissues. Previous studies point to a mitochondrial involvement in the action mechanism; however, the early steps have not been fully elucidated. In a model of acute promyelocytic leukemia (APL) derived from hCG-PML-RAR alpha transgenic mice, we demonstrated that alpha-TOS is as effective as arsenic trioxide or all-trans retinoic acid, the current gold standards of therapy. We also demonstrated that alpha-TOS induces an early dissipation of the mitochondrial membrane potential in APL cells and studies with isolated mitochondria revealed that this action may result from the inhibition of mitochondrial respiratory chain complex I. Moreover, alpha-TOS promoted accumulation of reactive oxygen species hours before mitochondrial cytochrome c release and caspases activation. Therefore, an in vivo antileukemic action and a novel mitochondrial target were revealed for alpha-TOS, as well as mitochondrial respiratory complex I was highlighted as potential target for anticancer therapy. Leukemia (2012) 26, 451-460; doi:10.1038/leu.2011.216; published online 26 August 2011 (AU)

FAPESP's process: 98/14247-6 - Center for Research on Cell-Based Therapy
Grantee:Marco Antonio Zago
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC